Kilitch Drugs (India) Limited Financial Ratios
KILITCH · Healthcare · Current price ₹231
P/E ratio
25.9x
P/B ratio
2.3x
ROE
10.8%
ROCE
12.0%
Debt / Equity
0.32
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 25.9x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 2.3x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 10.8% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 12.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.32 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Kilitch Drugs (India) Limited's latest numbers.
Kilitch Drugs (India) Limited profitability
Kilitch Drugs (India) Limited generates a return on equity of 10.8% and a return on capital employed of 12.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.32 and a P/E of 25.9x, Kilitch Drugs (India) Limited is conservatively financed. Our overall business-quality score for the company is 5.2 / 10.
Understand the ratios
More on Kilitch Drugs (India) Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.